

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2011
(Rs.in Lakhs)

	Particulars	STANDALONE				
		Quarter ended		Half Year ended		Year Ended
		30.09.2011	30.09.2010	30.09.2011	30.09.2010	31.03.2011
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	35408	25330	71263	51584	130544
	(b) Other Operating Income	1198	355	1824	631	1247
	<u>Total Income</u>	36606	25685	73087	52215	131791
2	<u>Expenditure:</u>					
	a. (Increase) / Decrease in Stock- in-Trade and Work-in-Progress	(469)	877	(4095)	(547)	3452
	b. Consumption of Raw Material	14893	9455	32801	21033	48668
	c. Purchase of Traded Goods					0
	d. Employees Cost	2381	1862	4828	3599	8049
	e. Depreciation	1520	1327	2920	2638	5335
	f. Other Expenditure					
	- Manufacturing Expenses	3066	2518	6060	4642	10207
	- Other expenses	2916	2140	6274	4371	10722
	g. Total	24307	18179	48788	35736	86433
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	12299	7506	24299	16479	45358
4	Other Income	1076	596	2091	1086	2613
5	Profit before Interest & Exceptional Items (3+4)	13375	8102	26390	17565	47971
6	Finance Charges	59	52	81	107	66
7	Profit after Interest but before Exceptional Items (5-6)	13316	8050	26309	17458	47905
8	Exceptional items	0	0	0	0	0
9	<u>Profit from ordinary activities before Tax (7-8)</u>	13316	8050	26309	17458	47905
10	Tax Expense					
	- Current Tax	2445	691	4910	1410	3920
	- MAT Credit Utilisation	125	78	385	73	128
	- Deferred Tax	141	(15)	150	50	300
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	10605	7296	20864	15925	43557
12	Extra-ordinary items	0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	10605	7296	20864	15925	43557
14	Paid-up Equity Share Capital (Face Value: Rs.2 each)	2653	2651	2653	2651	2652

15	Reserves excluding revaluation reserves					180153
16	Earnings per Share					
a)	Basic Earnings Per Share before extra-ordinary items Rs.	8.00	5.52	15.73	12.05	32.90
	Diluted Earnings Per Share before extra-ordinary items Rs.	7.99	5.52	15.73	12.04	32.88
b)	Basic Earnings Per Share after extra-ordinary items Rs.	8.00	5.52	15.73	12.05	32.90
	Diluted Earnings Per Share after extra-ordinary items Rs.	7.99	5.52	15.73	12.04	32.88
17	Public shareholding:					
	- No. of shares	63454450	63346140	63454450	63346140	63372210
	- % of shareholding	47.83%	47.80%	47.83%	47.80%	47.79%
18	Promoters and promoter group shareholding:					
	a) pledged / encumbered	Nil	Nil	Nil	Nil	Nil
	b) non-encumbered:					
	No. of shares	69222100	69185100	69222100	69185100	69222900
	Percentage of shares (as a % of the total shareholding of the promoter group)	100%	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	52.17%	52.20%	52.17%	52.20%	52.21%

Statement of Assets and Liabilities:

(Rs.in Lakhs)

	Particulars	STANDALONE		
		As at		As at
		30.09.2011	30.09.2010	31.03.2011
		Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)
1	SHAREHOLDERS' FUNDS:			
	a) Capital	2653	2651	2652
	b) Reserves and Surplus	201090	167869	180153
	LOAN FUNDS	2715	2137	2304
	DEFERRED TAX - NET	5642	5240	5491
	TOTAL	212100	177897	190600
	FIXED ASSETS	79657	64669	71906
	INVESTMENTS	46384	42155	52845
	CURRENT ASSETS, LOANS AND ADVANCES:			
	a) Inventories	60991	50792	54307
	b) Sundry Debtors	33086	21886	39495
	c) Cash and Bank Balances	1467	1024	1280
	d) Other Current Assets	28	21	30
	e) Loans and Advances	15888	11589	10950
	Less: CURRENT LIABILITIES AND PROVISIONS:			
	a) Liabilities	24569	13772	24032
	b) Provisions	832	467	16181
	NET CURRENT ASSETS	86059	71073	65849
	MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	Nil	Nil	Nil
	TOTAL	212100	177897	190600

NOTES:

1. The above results for the period ended 30th September 2011, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 1st November, 2011 and were subjected to 'limited review' by the Auditors.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 notified under the Companies Act, 1956.
3. As per Clause 41 of the listing agreement, the company has opted to publish quarterly unaudited Standalone Results and to publish consolidated results at the year end.
4. Figures for the previous year/period have been regrouped or recasted, wherever necessary.
5. During the current quarter, the company has allotted 26,520 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.09.2011:

Opening: Nil, Received during the Quarter: 34, Resolved: 34, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 01-11-2011

Dr. Murali K. Divi
Chairman & Managing Director